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Abstract
Background: Optimal glycaemic targets for patients with severe traumatic brain injury remain unclear. The
primary objective of this microdialysis study was to compare cerebral metabolism with strict versus
conventional glycaemic control.
Methods: We performed a prospective single-centre randomised controlled within-subject crossover study of 20 adult
patients admitted to an academic neurointensive care unit with severe traumatic brain injury. Patients underwent
randomised, consecutive 24-h periods of strict (4–7 mmol/L; 72–126 mg/dl) and conventional (<10 mmol/L; 180 mg/
dl) glycaemic control with microdialysis measurements performed hourly. The first 12 h of each study period was
designated as a ‘washout’ period, with the subsequent 12 h being the period of interest.
Results: Cerebral glucose was lower during strict glycaemia than with conventional control (mean 1.05 [95% CI 0.58–1.
51] mmol/L versus 1.28 [0.81–1.74] mmol/L; P = 0.03), as was lactate (3.07 [2.44–3.70] versus 3.56 [2.81–4.30]; P < 0.001).
There were no significant differences in pyruvate or the lactate/pyruvate ratio between treatment phases. Strict glycaemia
increased the frequency of low cerebral glucose (< 0.8 mmol/L; OR 1.91 [95% CI 1.01–3.65]; P < 0.05); however, there were
no differences in the frequency of critically low glucose (< 0.2 mmol/L) or critically elevated lactate/pyruvate ratio
between phases.
Conclusions: Compared with conventional glycaemic targets, strict blood glucose control was associated with lower
mean levels of cerebral glucose and an increased frequency of abnormally low glucose levels. These data support
conventional glycaemic targets following traumatic brain injury.
Trial registration: ISRCTN, ISRCTN19146279. Retrospectively registered on 2 May 2014.
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Background
Hyperglycaemia occurs frequently following traumatic
brain injury (TBI) and is associated with poor outcomes
[1–3]. While it is well established that marked acute
hyperglycaemia drives secondary brain injury following
the initial traumatic insult [4], the magnitude of the ele-
vation in blood glucose required to cause harm remains
uncertain. Current management of hyperglycaemia in
TBI involves the use of intravenous infusions of short-
acting insulin, titrated to maintain systemic blood glu-
cose within target ranges that have largely been derived
from randomised controlled trials in general medical,
surgical or heterogeneous critically ill populations [5].
The appropriateness of applying these targets to an
exclusively TBI population has been questioned as the
injured brain has a heightened susceptibility to both
hyper and hypoglycaemia [6, 7]. Furthermore, a small
number of studies examining surrogate outcomes of
cerebral glucose metabolism have suggested that inten-
sive glycaemic control is associated with deleterious
effects in patients with severe TBI, specifically an
increased prevalence of brain energy crisis [8–10]. How-
ever, at present there is insufficient evidence to guide
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clinical practice, highlighted by the lack of a recom-
mended glucose target in the latest iteration of the Brain
Trauma Foundation’s Guidelines of the Management of
Severe Traumatic Brain Injury [11].
Using cerebral microdialysis, the primary objective of
this prospective randomised controlled within-subject
crossover study was to compare cerebral glucose metabo-
lism between strict and conventional glucose control; spe-
cifically this included comparisons of cerebral glucose,
lactate, pyruvate and the lactate/pyruvate (L:P) ratio. The
secondary objective was to determine the frequency of
pathologically abnormal brain chemistry parameters
between treatment phases.
Methods
Twenty patients aged >16 years with TBI necessitating
intensive care management and intracranial pressure
(ICP) monitoring were recruited from the Neurosciences
Critical Care Unit at Addenbrooke’s Hospital,
Cambridge, UK. Recruitment occurred over two phases
with ten patients recruited between August 2007 and
September 2008 and ten patients recruited between
August 2010 and June 2011. Written, informed assent was
obtained from the patients’ next of kin. Exclusion criteria
were a past medical history of diabetes mellitus (type 1 or
type 2), life threatening injury where the patient was not
expected to survive >48 h and pregnancy. The study was
approved by the Cambridge Local Research Ethics
Committee (LREC number 06/Q0108/215).
General management protocol
All patients were intubated, mechanically ventilated and
managed according to a standardised tiered head injury
protocol [12, 13]. The intensity of treatment was titrated
to maintain ICP <20 mmHg and cerebral perfusion pres-
sure (CPP) >60–70 mmHg. Therapeutic options included
head elevation, analgesia, sedation, muscle relaxation, ven-
triculostomy, moderate hyperventilation (partial pressure
of carbon dioxide in arterial blood ≥ 4.0 kPa, 30 mmHg),
osmotic agents, mild to moderate hypothermia (35–33 °C),
CPP augmentation with vasopressors and, at the last stage,
barbiturate coma and decompressive craniectomy. CPP
was calculated as the difference between mean arterial pres-
sure (MAP) and ICP.
Monitoring
MAP was measured invasively via an arterial line with
the transducer zeroed at the level of the tragus. All pa-
tients underwent monitoring of ICP with parenchymal
ICP microsensors (Codman, Raynham, USA) and cere-
bral extracellular chemistry with microdialysis catheters
(CMA70 and CMA71; CMA Microdialysis AB, Solna,
Sweden). The sensors were inserted via a triple lumen
access device (Technicam, Newton Abbot, UK), placed
routinely in the frontal area of the right hemisphere
unless clinical circumstances dictated another position.
The CMA71 and CMA70 microdialysis catheters were
perfused with central nervous system perfusion fluid at
the standard rate of 0.3 μl/minute, with a sampling inter-
val of 1 h [14]. Analysis for glucose, lactate and pyruvate
was performed using bedside CMA 600 or ISCUS
analysers.
ICP monitoring was performed at the bedside using
ICM+ software (ICM+, University of Cambridge), which
in addition to recording physiological variables (ICP, MAP
and CPP) allowed online calculation of the cerebrovascu-
lar pressure reactivity index (PRx). The PRx represents a
moving correlation coefficient between 30 mean values of
ICP and MAP, recorded at 10 second intervals, and
reflects the state of cerebral vascular autoregulation; a
negative correlation implies active pressure reactivity
while a positive correlation suggests autoregulatory
impairment [13, 14].
Glucose protocol
Following admission to the intensive care unit (ICU), all
patients were initially treated with a blood glucose con-
trol protocol using continuous infusions of intravenous
insulin to target a blood glucose level <10 mmol/L (180
mg/dl) with serial arterial blood glucose measured 1- to
2-hourly (Roche OmniS, Massachusetts, USA) depen-
ding on glucose stability. Patients were randomised via
computer generated assignment to an initial 24-hr
period of ‘strict normoglycaemia’, (blood glucose
maintained between 4–7 mmol/L; 72–126 mg/dl)
[15], or conventional glucose control (<10 mmol/L;
180 mg/dl), following which they crossed-over to the
alternate glycaemic target for the second 24 h period
of observation with all subjects completing both arms
of the crossover (Additional file 1: Figure S1 and
Additional file 2: Figure S2). The first 12 h of each
study period was defined as the ‘washout’ phase with
the second 12 h designated a priori as the capture
period of interest. Supplemental intravenous dextrose
was not administered unless patients became
hypoglycaemic (glucose <4 mmol/L, 72 mg/dl).
Data processing and statistical analysis
Data were examined for known artifacts associated with
flushing of the arterial line, temporary disconnection
and refilling of perfusion fluid, which were manually re-
moved [14]. Microdialysis values outside of the analytical
range of the CMA-600 or ISCUS analysers (CAN, Solna,
Sweden) were deemed erroneous and excluded from
analysis. Summary data are presented as number (%),
mean (SD) or median [IQR] as indicated. Management
phase by time effects were assessed with mixed effects
linear modelling and subsequent between phase
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comparisons performed as population-averaged effects
using general estimating equations to account for re-
peated measures within subject; data are presented as
mean (95% confidence interval). Agreement between
categories was assessed using Cohen’s kappa. An α level
of 0.05 was considered statistically significant. All
analyses were performed in Stata MP 14.1.
The 2014 International Microdialysis Forum brain
chemistry thresholds were used to define abnormal brain
chemistry values; glucose <0.2 and 0.8 mmol/L, lactate
>4 mmol/L and L:P ratio >25 and >40 [16]. Two sepa-
rate binary logistic models were used at the pre-defined
glucose microdialysis cut-points of <0.8 and <0.2.
Results
Twenty patients were enrolled in the study with clinical
details as outlined in Table 1. The cohort included 15
males, the median age was 34 [23, 50] years, Acute
Physiology and Chronic Health Evaluation II score 20.5
[14.5, 23.0], injury severity score 29 [23, 40] and initial
Glasgow Coma Scale score of 5 [3, 8]. ICU length of stay
was 23 [17, 18] days. Two patients died on days 5 and 8,
respectively. The interval between injury and initiation
of microdialysis monitoring was 4.5 [3, 8] days and
monitoring was continued for 4 [3, 9] days. Review of
computed tomographic scans revealed that the microdi-
alysis tip was sited in normal-appearing parenchyma in
19 patients and in peri-lesional tissue in one patient.
Mixed-effects linear models looking for treatment
phase-by-time effects were non-significant, and plots of
the mean variable profiles during the treatment periods
were uniform. Between-period analysis was therefore
undertaken for the population-averaged differences
using generalised estimating equations, allowing for
clustered measurements by patient.
Serum glucose
In the period of interest (i.e., hours 13–24), there was
clear separation in blood glucose profiles between the
treatment phases (Fig. 1). The mean (95% CI) blood glu-
cose level in the strict phase was 6.6 (6.2–7.1) mmol/L
compared with 8.4 (7.6–9.1) mmol/L in the conventional
phase (P < 0.001). There were two episodes of moderate
hypoglycaemia (< 4 mmol/L) occurring in the same pa-
tient during strict glycaemia, and there were no episodes
of severe hypoglycaemia (≤ 2.2 mmol/L) in either phase.
Fourteen patients (70%) required exogenous insulin
during the conventional phase, and 17 patients (85%) re-
quired insulin during the strict phase. The period of
strict glycaemia was associated with greater exogenous
Table 1 Clinical profile of study group
Patient Age (years) Sex GCS score APACHE II score ISS CT scan result ICU days GOSa
1 16 Male 3 27 41 Evacuated ML 27 SD
2 32 Male 5 16 48 Diffuse 50 –
3 24 Male 3 23 25 Evacuated ML 25 –
4 54 Male 8 21 25 Non-evacuated ML 26 SD
5 39 Male 3 23 38 Diffuse 23 G
6 22 Female 11 15 9 Non-evacuated ML 12 MD
7 49 Female 5 22 17 Evacuated ML 25 G
8 55 Male 3 24 34 Diffuse 21 SD
9 22 Female 3 26 25 Non-evacuated ML 32 –
10 56 Female 8 13 16 Non-evacuated ML 21 G
11 18 Male 3 29 34 Diffuse 8 D
12 58 Male 3 9 45 Evacuated ML 5 D
13 18 Male 9 14 25 Diffuse 10 –
14 25 Male 4 17 29 Non-evacuated ML 40 SD
15 27 Male 8 23 29 Diffuse 30 –
16 43 Male 5 17 34 Diffuse 20 –
17 41 Male 12 8 16 Diffuse 15 MD
18 36 Female 10 8 20 Non-evacuated ML 19 G
19 50 Male 4 21 57 Diffuse 23 –
20 23 Male 3 20 57 Non-evacuated ML 44 –
Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II, GCS Glasgow Coma Scale, GOS Glasgow Outcome Scale, ICU Intensive care unit, ISS
Injury Severity Score
a Glasgow Outcome Scale score at 6 months: D died, G good, MD moderate disability, ML mass lesion, PVS persistent vegetative state SD Severe disability
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insulin infusion requirements: mean (95% CI) insulin in-
fusion rates were 3.6 (2.2–5.0) units/hr vs. 1.1 (0.6–
1.5) units/hr (P = 0.01) (Fig. 2).
Microdialysis results
For the strict and conventional phases, there were
10.0 [9.5–11.0] and 10.5 [9.0–11.0] time points (of a
possible 12) with complete cerebral microdialysis data
for glucose, lactate and pyruvate. Microdialysis glu-
cose was lower during the strict glycaemic phase
(1.05 [0.58–1.51] mmol/L versus 1.28 [0.81, 1.74]
mmol/L; P = 0.03), as was lactate (3.07 [2.44–3.70]
versus 3.56 [2.81–4.30]; P < 0.001). There were no
significant differences in pyruvate or the lactate/pyru-
vate (L:P) ratio between treatment phases.
Relationship between plasma glucose, microdialysis
glucose and insulin
For a given level of arterial blood glucose, there was no
association between insulin infusion rate and cerebral
glucose (P = 0.3).
Frequency of abnormal brain chemistry by treatment
phase
Strict blood glucose control was associated with an
increased rate of low cerebral glucose (< 0.8 mmol/L;
OR 1.91, 95% CI 1.01–3.65; P < 0.05). There were ten
episodes of critically low cerebral glucose < 0.2 mmol/
L (two in the conventional arm in one patient and
eight in the strict arm in six patients) (OR 4.03, 95%
CI 0.69–23.40; P = 0.12). There were no significant
differences in the frequency of abnormal L:P ratio or
lactate levels between treatment phases (Table 2). A
secondary analysis of the frequency of abnormal cere-
bral glucose was performed, dividing cerebral glucose
into discrete 0.2 mmol/L subgroups (Fig. 3). Emplo-
ying logistic regression, using cerebral glucose
values > 2 mmol/L as the base reference group and
adjusting for repeated measures, there was a trend
toward an increase in the frequency of low cerebral
glucose range of 0.21–0.4 mmol/L with strict control
(OR = 2.80, 95% CI 0.99–8.13; P = 0.05) (Additional
file 3: Figure S3).
Summary measures for recorded variables by glucose
management phase are provided in (Additional file 4:
Table S1). Employing multivariate modelling by tier
level, we observed that there were no associations
Fig. 1 Plasma glucose time course. Commencement of the period
of interest (hours 12–24) is designated by the vertical dashed line.
Treatment separation was achieved with lower blood glucose in the
strict phase (solid line) than in the conventional phase (dashed line):
6.6 (6.6–7.1) mmol/L vs. 8.4 (7.6–9.1) (P < 0.001). Data are presented
as mean (95% CI)
Fig. 2 Insulin dose time course. Commencement of the period of
interest (hours 12–24) is designated by the vertical dashed line. Strict
glycaemia was associated with greater exogenous insulin infusion
requirements; insulin infusion rates were 3.6 (2.2–5.0) vs. 1.1 (0.6–1.5)
(P = 0.01). Data are presented as mean (95% CI)
Table 2 Measurement frequencies for International Microdialysis
Forum Tier 1 substances, by treatment phase
Group Normala Stricta Total P valueb
Glucose (mmol/L) > 0.8 110 (6) 78 (42) 188 (50) 0.22
0.2–0.8 79 (41) 102 (54) 181 (48)
< 0.2 2 (1) 8 (4) 10 (3)
191 188 379
Lactate/pyruvate ratio < 25 83 (42) 116 (60) 199 (51) 0.32
25–40 101 (52) 67 (35) 168 (43)
> 40 12 (6) 9 (5) 21 (5)
196 192 388
Lactate (mmol/L) < 4 142 (73) 156 (81) 298 (77) 0.69
≥ 4 54 (28) 36 (19) 90 (23)
196 192 388
a Cells are shown as number (percent) for single measurements
b Probability of group effect between treatment phases by chi-square test for
generalised estimating equation estimates, using a binomial distribution and
logit link, clustered by patient
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between systemic covariates (insulin dose, partial pres-
sure of oxygen, partial pressure of carbon dioxide, ICP,
CPP, PRx, plasma glucose and plasma lactate) and
markers of abnormal brain chemistry. Agreement be-
tween group levels of abnormal glucose and L:P ratio
was poor (κ = 0.13), and there were no measurements
with concurrent glucose and L:P ratio indicators of
cerebral metabolic distress (glucose < 0.2 mmol/L and
L:P ratio > 40).
Discussion
The key finding of this study was that strict normo-
glycaemia, targeting a plasma glucose < 7 mmol/L
(126 mg/dl), is associated with lower cerebral glucose
than conventional control targeting < 10 mmol/L (180
mg/dl). There is only one previous prospective study
in a TBI population providing data on brain chemistry
performance according to systemic blood glucose
targets [10]. In this vanguard microdialysis trial, using
a within-subject crossover design, Vespa et al. [10]
randomised 13 patients with severe TBI to periods of
both ‘tight’ (4.4–6.1 mmol/L; 80–110 mg/dl) and
‘loose’ glycaemic control (6.7–8.3 mmol/L; 120–150
mg/dl). They reported an increase in metabolic dis-
tress during tight glycaemic control as determined by
the proportion of time with critically low glucose or
critically elevated L/P ratio [10]. By performing
concurrent glucose-labelled positron emission tomog-
raphy, they were able to demonstrate an increase in
glucose metabolism during tight glycaemic control,
most prominently in normal brain tissue [10]. Hence,
loose glycaemic control was interpreted as being
preferable for cerebral metabolism. These data are
consistent with retrospective observational studies
demonstrating associations between tight glycaemic
control and microdialysis markers of cerebral meta-
bolic distress [8, 9].
Analysing cerebral glucose tier levels as simple binary
cut-points, strict glycaemic control increased the fre-
quency of low cerebral glucose (cerebral glucose < 0.8
mmol/L) but not critically low cerebral glucose (< 0.2
mmol/L), albeit that there were only ten events in the
critically low range. Similarly, by analysing blood glucose
in discrete 0.2 mmol/L subgroups, we demonstrated a
trend towards an increase in low blood glucose in the
range of 0.21–0.4 mmol/L with strict glycaemic control;
however, there was no difference between treatment
arms in the subgroup of critically low glucose < 0.2
mmol/L. This may represent a function of the small
sample size, given the low overall incidence of critically
low glucose measurements (n = 10 [2.6%]), and we can-
not exclude the possibility that a difference in cerebral
chemistry may have been demonstrated with a larger
sample. Furthermore, there were key differences in the
glycaemic thresholds targeted and achieved in the
present study compared with previous work in this area.
In their prospective study, Vespa et al. achieved mean
(SD) plasma glucose values of 6.1 (1.3) mmol/L, 110 (23)
mg/dl and 7.7 (1.6) mmol/L, and 139 (29) mg/dl in the
tight and ‘loose’ arms, respectively, reflecting contempor-
ary practice at the time. In contrast, the mean (95% CI)
values in the present study were 6.6 (6.1–7.1) mmol/L,
119 (111–127) mg/dl and 8.4 (7.6–9.1) mmol/L, and 151
(137–164) mg/dl. Importantly, in both studies, the mean
Fig. 3 Cerebral blood glucose. Cerebral blood glucose subdivided into 0.2 mmol/L groups. Thresholds for low (< 0.8 mmol/L) and critically low
(< 0.2 mmol/L) are designated by horizontal dashed lines. There was a trend towards increased frequency of low cerebral glucose in the 0.21–0.4
mmol/L range with strict glycaemia (OR 2.8, 95% CI 0.99–8.1; P = 0.05). CMD Cerebral microdialysis
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systemic glucose during periods of strict glycaemia were
towards the upper limit of the strict target range (6.1
and 6.6 mmol/L, respectively). Taken together, this sug-
gests that there is a signal for harm even at higher
thresholds of traditional tight glycaemia (i.e., a glucose
level of 6.0 mmol/L; 108 mg/dl).
The clinical relevance of this distinction is
highlighted by the movement away from the very
tight glycaemic targets advocated in the seminal blood
glucose trial by Van den Berghe et al. in 2001 [17].
This single-centre study in a surgical ICU population
resulted in a paradigm shift in the approach to blood
glucose management after demonstrating a marked
reduction in mortality targeting blood glucose levels
of 4.4–6.1 mmol/L; 80–110 mg/dl [17]. Despite the
initial enthusiasm for this regimen, subsequent multi-
centre randomised controlled trials not only failed to
replicate the survival benefit but also reported higher
incidences of severe hypoglycaemia [19–21] and an
increase in mortality with tight control [22]. Systematic re-
view of glycaemic targets in neurointensive care has dem-
onstrated that strict glucose control conveys no mortality
benefit compared with more liberal targets but may be as-
sociated with lower rates of poor neurological outcome
despite significantly higher rates of hypoglycaemia [23].
Importantly, data from the general ICU population sug-
gest that there is a strong dose-dependent relationship be-
tween hypoglycaemia and mortality [24]. Furthermore,
mechanisms of neuronal cell death following short periods
of hypoglycaemia are well established [25]. Consequently,
although consensus guidelines are lacking, few ICUs
would currently advocate targeting tight blood glucose
control following severe TBI. We report lower cerebral
glucose and a trend towards an increase in abnormally
low cerebral glucose (0.2–0.4 mmol/L) when targeting
systemic blood glucose of 4–7 mmol/L compared with
conventional targets. Accordingly, we continue to advo-
cate conventional glycaemic targets (< 10 mmol/L; 180
mg/dl) following acute TBI as per the NICE-SUGAR
investigators’ study [22].
As a secondary outcome, we report a poor correlation
between low brain glucose and high L:P ratio. Further-
more, we report no significant difference in the fre-
quency of abnormally elevated L:P ratio by treatment
phase. This differs from previous retrospective observa-
tional studies and randomised controlled trials in which
researchers reported strong associations between low
cerebral glucose and elevated L:P ratios, justifying com-
bining the two as a composite end-point of so-called
brain energy crisis [8–10, 26]. Our data question the ap-
propriateness of this classification, particularly because
the pathological mechanisms driving these two
phenomena are likely to differ. Although incompletely
understood, the L:P ratio is thought to reflect
mitochondrial dysfunction, whereas low glucose likely
results from increased substrate demand (i.e., greater
cellular uptake and glucose use [7]) or impaired delivery.
Finally, there was no relationship between exogenous in-
sulin administration and cerebral blood glucose. This is in
contradistinction to brain chemistry studies in subarach-
noid haemorrhage indicating that insulin administration
per se decreases cerebral glucose independently of systemic
glycaemia [27, 28]. Further studies of cerebral metabolic re-
sponsiveness to insulin during TBI are warranted.
There are several important limitations to this study.
First, although this represents the largest prospective study
in this area, it remains a small, single-centre study and
accordingly is subject to bias, including within-subject
differences such as concurrent treatments, position of the
microdialysis catheter, timing of monitoring, and extent
and severity of non-cerebral injuries. The small sample size
also increases the risk of a type II error, possibly supported
by the trend towards a significant difference in the low
cerebral glucose range 0.21–0.4 mmol/L. Second, the upper
95% CI for the strict glycaemic phase (7.1 mmol/L) fell
above the target range of < 7 mmol/L; although this is sub-
tle, we cannot exclude that more vigilant adherence to
‘strict normoglycaemia’ would result in a difference in brain
chemistry. Third, we did not perform continuous electroen-
cephalography and cannot exclude the possibility that sub-
clinical seizures may have influenced microdialysis results.
Fourth, the mean time to commencement of microdialysis
monitoring was 4.5 days. Accordingly, we may have failed
to capture the metabolic derangements in the acute phase
post-TBI. Temporal cerebral microdialysis studies indicate
a pattern of decline in cerebral glucose and a rise in cere-
bral lactate in the week post-TBI, with day 3 post-injury
thought to reflect the period of greatest metabolic demand
[13, 18]. We cannot exclude that results may differ in the
first 72 h post-TBI. Finally, because this is a microdialysis
study, the results are subject to the limitations inherent in
this focal monitoring technique whereby global assump-
tions of cerebral metabolism are derived from a limited
sampling area. Heterogeneity in glucose use between peri-
contusional and normal-appearing white matter is well
described, and the degree to which cellular metabolism is
oxygen-dependent is likely dynamic [7]. Multi-modality
studies are required to characterise with greater granularity
how altering glucose delivery influences neuronal metabo-
lism, both within the brain and throughout recovery.
Conclusions
In summary, strict normoglycaemia targeting a plasma
glucose < 7 mmol/L (126 mg/dl) is associated with lower
cerebral glucose than conventional control targeting < 10
mmol/L (180 mg/dl). There was an increase in low
cerebral glucose (< 0.8 mmol/L) during strict glycaemia
in secondary analysis. Future prospective studies
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employing larger sample sizes are required to further
characterise cerebral metabolism according to systemic
glycaemic targets.
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